2-chloro-4-(4-chloro-phenyl)-6-methyl-pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-chloro-4-(4-chloro-phenyl)-6-methyl-pyrimidine
• 英文别名: 2-chloro-4-methyl-6-(4-chloro-phenyl)-pyrimidine；2-chloro-4-(4-chlorophenyl)-6-methylpyrimidine
• 化学式: C₁₁H₈Cl₂N₂
• 分子量: 239.104
• InChiKey: PYVIXLOQDVXPSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloro-4-(4-chloro-phenyl)-6-methyl-pyrimidine 、 凝血酸 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 4-{[4-(4-chlorophenyl)-6-methyl-pyrimidin-2-ylamino]methyl}cyclohexanecarboxylic acid
  参考文献：
  名称：

  Discovery of 2-(Cyclohexylmethylamino)pyrimidines as a New Class of Reversible Valosine Containing Protein Inhibitors

  摘要：

  Valosine-containing protein (VCP), also known as p97 or cdc48 in yeast, is a highly abundant protein belonging to the AAA ATPase family involved in a number of essential cellular functions, including ubiquitin-proteasome mediated protein degradation, Golgi reassembly, transcription activation, and cell cycle control. Altered expression of VCP has been detected in many cancer types sometimes associated with poor prognosis. Furthermore, VCP mutations are causative of some neurodegenerative disorders. In this paper we report the discovery, synthesis, and structure-activity relationships of substituted 2-aminopyrimidines, representing a new class of reversible VCP inhibitors. This class of compounds, identified in a HTS campaign against recombinant VCP, has been progressively expanded and manipulated to increase biochemical potency and gain cellular activity.

  DOI：

  10.1021/jm501313x
• 作为产物：
  描述：

  2,4-二氯-6-甲基嘧啶 、 4-氯苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.25h， 生成 2-chloro-4-(4-chloro-phenyl)-6-methyl-pyrimidine
  参考文献：
  名称：

  Discovery of 2-(Cyclohexylmethylamino)pyrimidines as a New Class of Reversible Valosine Containing Protein Inhibitors

  摘要：

  Valosine-containing protein (VCP), also known as p97 or cdc48 in yeast, is a highly abundant protein belonging to the AAA ATPase family involved in a number of essential cellular functions, including ubiquitin-proteasome mediated protein degradation, Golgi reassembly, transcription activation, and cell cycle control. Altered expression of VCP has been detected in many cancer types sometimes associated with poor prognosis. Furthermore, VCP mutations are causative of some neurodegenerative disorders. In this paper we report the discovery, synthesis, and structure-activity relationships of substituted 2-aminopyrimidines, representing a new class of reversible VCP inhibitors. This class of compounds, identified in a HTS campaign against recombinant VCP, has been progressively expanded and manipulated to increase biochemical potency and gain cellular activity.

  DOI：

  10.1021/jm501313x

文献信息

• Pyridine and pyrimidine derivatives as mGIuR2 antagonists
  申请人：McArthur Silvia Gatti

  公开号：US20070232583A1

  公开（公告）日：2007-10-04

  The present invention relates to compounds of formula (I), a process for the manufacture thereof, pharmaceutical compositions containing them, and their use for treating CNS disorders: wherein A, B, X, Y, R 1 , R 2 , R 3 and R 4 are as defined in the description and claims.

  本发明涉及式(I)的化合物，其制造方法，含有它们的药物组合物，以及它们用于治疗中枢神经系统疾病的用途：其中A、B、X、Y、R1、R2、R3和R4如描述和权利要求中所定义。
• Compounds useful as chemokine receptor antagonists
  申请人：Carson G. Kenneth

  公开号：US20060172994A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.

  本发明涉及作为趋化因子受体拮抗剂有用的化合物。提供了一般式I的化合物：或其药学上可接受的盐。本发明还提供了包含所述化合物的药学上可接受的组合物以及使用所述化合物和组合物抑制趋化因子受体以及治疗各种疾病、病症或紊乱的方法，包括急性或慢性炎症性疾病、癌症或骨溶解性骨病。
• PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS
  申请人：Gatti McArthur Silvia

  公开号：US20090318474A1

  公开（公告）日：2009-12-24

  The present invention relates to compounds of formula (I), a process for the manufacture thereof, pharmaceutical compositions containing them, and their use for treating CNS disorders: wherein A, B, X, Y, R 1 , R 2 , R 3 and R 4 are as defined in the description and claims.

  本发明涉及化合物的公式（I），其制造过程，包含它们的药物组合物，以及用于治疗中枢神经系统疾病的方法：其中A、B、X、Y、R1、R2、R3和R4如描述和权利要求所定义。
• Pyridine derivatives as mGluR2 antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US08183262B2

  公开（公告）日：2012-05-22

  The present invention relates to compounds of formula (I), a process for the manufacture thereof, pharmaceutical compositions containing them, and their use for treating CNS disorders: wherein A, B, X, Y, R1, R2, R3 and R4 are as defined in the description and claims.

  本发明涉及式(I)的化合物，其制造方法，含有它们的制药组合物，以及它们用于治疗中枢神经系统疾病的用途：其中A、B、X、Y、R1、R2、R3和R4如描述和权利要求中所定义。
• Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
  申请人：Carson Kenneth G.

  公开号：US20110237601A1

  公开（公告）日：2011-09-29

  The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.

  本发明涉及作为趋化因子受体拮抗剂有用的化合物。提供了一般式I的化合物：或其药学上可接受的盐。本发明还提供了包含所述化合物的药学上可接受的组合物，以及使用这些化合物和组合物抑制趋化因子受体，并用于治疗各种疾病、病况或障碍的方法，包括急性或慢性炎症性疾病、癌症或溶骨性骨疾病。